drugset / Trial / NCT06113731
A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine
RandomizedParallel-groupQuadruple-blindPrevention
Summary
To evaluate the immunogenicity and safety of a COVID-19 mRNA vaccine (ZSVG-02-O) in a healthy population aged 18 years and older.
Timeline
- Start
- 2023-07-10
- Primary completion
- 2023-10-30
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CoronaVac | Vaccine | — | — |
| Subject | ZSVG-02-O | Messenger RNA (mRNA) | 30 ug | — |
| Subject | ZSVG-02-O | Messenger RNA (mRNA) | 60 ug | — |